Home > Expanded Access > Master Rollover Protocol for Continued Safety Assessment of Study Drug

Eli Lilly and Company

Master Rollover Protocol for Continued Safety Assessment of Study Drug

Official Title: 
Master Rollover Protocol for Continued Safety Assessment of Study Drug
Brief Summary: 
This study is for patients who have participated in a previous study and who continue to receive benefit to have continued access to study drug and/or treatment.
Available
Cancer

Drug: LY2503029
Administered orally.

Eligibility Criteria: 

Inclusion Criteria:

- To be eligible patients must be currently receiving benefit in a Lilly study that has met its endpoints or has otherwise stopped.

Exclusion Criteria:

- Patients must not be concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.

Eligibility Gender: 
All
Eligibility Age: 
Minimum: 18 Years
Countries: 
United States
Locations: 

Tennessee Oncology
Nashville, Tennessee, 37203

Investigator: There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Contact: 317-615-4559

Contacts: 

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT -5 hours, EST)
Study Director
Eli Lilly and Company

Eli Lilly and Company
EA Number: 
Disclaimer:
Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.